▶주메뉴 바로가기
▶본문 바로가기
SK Biopharmaceuticals, a drug development unit of South Korea’s telecom-to-energy conglomerate SK Group , announced on April 18 that it has signed a contract with US-based biotech company twoXAR to...
Attempts to open a for-profit hospital in South Korea have collapsed, portending a long-drawn legal battle between Jeju Self-Governing Province and a Chinese group that feels betrayed. The approval ...
Korea Health Industry Development Institute announced on April 17 that it is hosting the Bio Korea International Convention from April 17-19. Session coordinators, including Bridge Bio CEO Lee Jung-...
NeoImmuneTech, an immunotherapy drug development company, announced on April 16 that its drug candidate HyLeukin-7 has been designated an orphan drug by the US Food and Drug Administration. HyLeukin...
Celltrion announced on April 11 that it has obtained marketing authorization from Health Canada for Truxima, its biosimilar for treating non-Hodgkin’s lymphoma. Truxima references Roche’s Rituxan (...
The share price of beleaguered Kolon Group ’s bio affiliates fluctuated after it announced its decision to suspend sales of Kolon Life Science’s new osteoarthritis drug Invossa on April 1 following...
An affiliate of South Korean biopharmaceutical firm Celltrion said Wednesday that the market share of its biosimilar Herzuma reached 10 percent in Europe during the fourth quarter of last year. C...
Korean health care startup Sky Labs aims to launch its Cardio Tracker, or CART, a ring-type wearable device that detects a patient’s heart rhythm 24/7 using internet of things technologies. “From th...
SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group , is gearing up to go public on the main bourse Kospi. According to industry sources, ...
GC Pharma announced on April 4 that it has signed a deal with Clinigen KK in Japan to license out its Hunter syndrome treatment Hunterase ICV. Hunter syndrome is a rare genetic disorder that interfe...
Kolon Life Science announced on April 1 that it has decided to suspend sales of its new osteoarthritis drug Invossa. According to the company, the decision was made after the its US unit Kolon Tiss...
South Korea’s bio sector is gaining both attention and traction, with many claiming their successful global expansion. While not all of them can deliver on their word, Daewoong Pharmaceutical is on...
Celltrion ’s founder and Chairman Seo Jung-jin announced on March 26 that the company aims to begin selling its biosimilar Truxima in the US within the second half of this year. Seo -- who is in To...
National Pension Service has decided to oppose key proposals by Samsung Biologics ahead of the company’s scheduled shareholders meeting on March 22. The key proposals include approval of the financi...
SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group, announced on March 21 that it has received marketing approval from the US Food and Drug ...
Netmarble Q2 net more than doubles on new games
Notion unveils Korean version to tap into 2nd-largest market
Gooroome lands W2b in pre-A round funding
Talks for HDC-Asiana deal likely to prolong
LG U+ to roll out 5G-powered AR glass service with Nreal
HMM sells stake in Algeciras terminal
SK makes world’s 1st NCM battery with 90% nickel
STIC Investments, Amorepacific and more - this week’s startup and investment update
August 12, 2020
![[INTERVIEW] Sky Labs aims to launch CART in Europe this year](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=155&simg=/content/image/2019/04/09/20190409000869_p.jpg)
![[ANALYSIS] Market upbeat on Daewoong’s prospects for this year](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=155&simg=/content/image/2019/03/27/20190327000790_p.jpg)
